102 related articles for article (PubMed ID: 276346)
1. Blocking factors against melanoma leucocyte-dependent antibody: relationship to disease activity in melanoma patients.
Hersey P; Murray E; Ruygrok S; Edwards A; Milton GW
Aust N Z J Surg; 1978 Feb; 48(1):26-32. PubMed ID: 276346
[TBL] [Abstract][Full Text] [Related]
2. Blocking factors against leucocyte-dependent melanoma antibody in the sera of melanoma patients.
Murray E; McCarthy WH; Hersey P
Br J Cancer; 1977 Jul; 36(1):7-14. PubMed ID: 19029
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of leukocyte-dependent antibody activity in melanoma patients.
Hersey P; Edwards A; Murray E; McCarthy WH; Milton GW
J Natl Cancer Inst; 1983 Jul; 71(1):45-53. PubMed ID: 6575208
[TBL] [Abstract][Full Text] [Related]
4. Detection of carcinoembryonic-like antigen on melanoma cells by leucocyte-dependent-antibody assays.
Morgan G; McCarthy WH; Hersey P
Br J Cancer; 1977 Oct; 36(4):446-52. PubMed ID: 73378
[TBL] [Abstract][Full Text] [Related]
5. Antibody-dependent cell-mediated cytotoxicity against melanoma cells induced by plasmapheresis.
Hersey P; Isbister J; Edwards A; Murray E; Adams E; Biggs J; Milton GW
Lancet; 1976 Apr; 1(7964):825-8. PubMed ID: 56647
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of vaccinia melanoma cell lysates (VMCL) as adjuvant to surgical treatment of stage II melanoma. II. Effects on cell mediated cytotoxicity and leucocyte dependent antibody activity: immunological effects of VMCL in melanoma patients.
Hersey P; Edwards A; D'Alessandro G; MacDonald M
Cancer Immunol Immunother; 1986; 22(3):221-31. PubMed ID: 3460702
[TBL] [Abstract][Full Text] [Related]
7. Leukocyte adherence inhibition and specific immunoreactivity in malignant melanoma.
Halliday WJ; Maluish AE; Little JH; Davis NC
Int J Cancer; 1975 Oct; 16(4):645-58. PubMed ID: 51836
[TBL] [Abstract][Full Text] [Related]
8. Antibody-dependent cell-mediated cytotoxicity for human monolayer target cells bearing blood group and transplantation antigens and for melanoma cells.
Kodera Y; Bean MA
Int J Cancer; 1975 Oct; 16(4):579-92. PubMed ID: 1080751
[TBL] [Abstract][Full Text] [Related]
9. Detection of anti-tumour cell mediated immunity and serum blocking factors in cancer patients by the leucocyte adherence inhibition test.
Halliday WJ; Maluish A; Isbister WH
Br J Cancer; 1974 Jan; 29(1):31-5. PubMed ID: 4820944
[TBL] [Abstract][Full Text] [Related]
10. Detection of a low-molecular-weight antigen on melanoma cells by a human antiserum in leukocyte-dependent antibody assays.
Hersey P; Murray E; Werkmeister J; McCarthy WH
Br J Cancer; 1979 Oct; 40(4):615-27. PubMed ID: 91379
[TBL] [Abstract][Full Text] [Related]
11. Analysis of serum blocking factors against leukocyte dependent antibody in melanoma patients.
Murray E; Ruygrok S; Milton GW; Hersey P
Int J Cancer; 1978 May; 21(5):578-87. PubMed ID: 350780
[No Abstract] [Full Text] [Related]
12. Sequential studies of melanoma leukocyte-dependent antibody activity in melanoma patients.
Hersey P; Edwards AE; Murray E; McCarthy WH; Milton GW
Eur J Cancer (1965); 1978 Jun; 14(6):629-37. PubMed ID: 658086
[No Abstract] [Full Text] [Related]
13. Tube leukocyte (monocyte) adherence inhibition assay for the detection of anti-tumour immunity. III. "Blockade" of monocyte reactivity by excess free antigen and immune complexes in advanced cancer patients.
Grosser N; Thompson DM
Int J Cancer; 1976 Jul; 18(1):58-66. PubMed ID: 59711
[TBL] [Abstract][Full Text] [Related]
14. Antigens on melanoma cells detected by leukocyte dependent antibody assays of human melanoma antisera.
Hersey P; Honeyman M; Edwards A; Adams E; McCarthy WH
Int J Cancer; 1976 Nov; 18(5):564-73. PubMed ID: 62719
[TBL] [Abstract][Full Text] [Related]
15. Early onset of serum blocking in a murine melanoma model.
Bray AE; Holt PG; Roberts LM; Keast D
Int J Cancer; 1975 Oct; 16(4):607-15. PubMed ID: 1176208
[TBL] [Abstract][Full Text] [Related]
16. Isolation and immunochemical characterization of antibodies from the sera of cancer patients which are reactive against human melanoma cell membranes by affinity chromatography.
Gupta RK; Silver HK; Reisfeld RA; Morton DL
Cancer Res; 1979 May; 39(5):1683-95. PubMed ID: 427806
[TBL] [Abstract][Full Text] [Related]
17. Serum blocking factor as an index of metastatic spread following primary tumour excision.
Bray AE; Holt PG
Eur J Cancer (1965); 1975 Dec; 11(12):855-60. PubMed ID: 767115
[No Abstract] [Full Text] [Related]
18. Induction of IgG antibodies directed to a M(r) 31,000 melanoma antigen in patients immunized with vaccinia virus melanoma oncolysates.
Berthier-Vergnes O; Portoukalian J; Lefthériotis E; Doré JF
Cancer Res; 1994 May; 54(9):2433-9. PubMed ID: 8162593
[TBL] [Abstract][Full Text] [Related]
19. The cell-mediated immunity in patients with malignant melanoma.
Fixa B; Komárková O; Kraus Z; Simková H
Neoplasma; 1978; 25(3):353-7. PubMed ID: 683378
[TBL] [Abstract][Full Text] [Related]
20. Clinical and immunological significance of human melanoma cytotoxic antibody.
Bodurtha AJ; Chee DO; Laucius JF; Mastrangelo MJ; Prehn RT
Cancer Res; 1975 Jan; 35(1):189-93. PubMed ID: 1109788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
